Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

The Food and Drug Administration approved the first injectable HIV prevention medication, which could be a massive step forward in ending the long-term epidemic.

In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States – but “even though PrEP has ...

Uncertain access The FDA's decision makes lenacapavir available today in the U.S., which sees about 31,000 of the 1.3 million new HIV infections each year worldwide.

While Truvada has been approved since 2004 as a treatment for those already infected with the HIV virus, this is the first time any drug has been approved for pre-exposure prophylaxis, or PrEP.

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

The Food and Drug Administration on Wednesday approved a powerful new drug that provides almost complete protection against HIV infections. The twice-yearly injection, known as lenacapavir, offers ...